Cardiovascular

FDA recommends more conservative dosing guidelines for erythropoiesis-stimulating agents

The U.S. Food and Drug Administration (FDA) is recommending more conservative dosing guidelines for erythropoiesis-stimulating agents (ESAs) when they are used to treat anemia in patients with chronic kidney disease. FDA cites increased risks of stroke and other cardiovascular events as the reason behind the change. Read more.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Shares